The Drug That Just Became the First Treatment for Every Type of This Rare Disease
Argenx's Vyvgart just became the first drug approved for every subtype of generalized myasthenia gravis, closing a gap that left 20% of patients without a targeted therapy. The $4.2 billion franchise keeps pulling further ahead of the competition.
Imagine being diagnosed with a disease that slowly steals your ability to swallow, breathe, and move your arms. Now imagine being told that the treatments on the market weren't designed for your version of it. That's been reality for roughly 20% of people with generalized myasthenia gravis (gMG), a rare autoimmune disease that causes debilitating muscle weakness.
Until now.
The 20% Nobody Could Treat
Generalized myasthenia gravis works like this: your immune system produces rogue antibodies that attack the connection between your nerves and muscles. Most patients (about 80%) test positive for a specific antibody called anti-AChR. Doctors have had targeted therapies for those patients since argenx's Vyvgart won FDA approval back in December 2021.
But here's the problem. The remaining patients fall into three other buckets: some carry anti-MuSK antibodies, some carry anti-LRP4 antibodies, and some test negative for all three (hence the name "triple seronegative"). These patients have the same brutal symptoms, the same progressive muscle weakness, the same fear of respiratory failure. They just have different biological fingerprints driving the disease.
For years, they've been stuck cobbling together off-label treatments and hoping for the best. No FDA-approved therapy was specifically designed for them.
On May 8, 2026, that changed.
Vyvgart Gets the Broadest Label in MG History
The FDA approved a major label expansion for Vyvgart (efgartigimod alfa-fcab) and its subcutaneous sibling, Vyvgart Hytrulo, making them the first and only FDA-approved treatments for all serotypes of adult gMG. Every flavor. Every antibody subtype. Even triple seronegative patients who previously had zero targeted options.
The approval came after the FDA granted Priority Review to argenx's supplemental Biologics License Application (sBLA) back in January 2026. Priority Review is the FDA's way of saying, "We think this could be a meaningful advance, so let's move faster." It compresses the typical review timeline from ten months down to six.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The agency doesn't hand out Priority Review like free samples at Costco. To qualify, a drug must show potential for significant improvement in safety or effectiveness for a serious condition, compared to what's already available. When the existing options for seronegative gMG patients were essentially "good luck," the bar for "significant improvement" was sitting on the floor.
The Trial That Made It Possible
The approval rested on data from the Phase 3 ADAPT SERON trial, a randomized, double-blind, placebo-controlled study that enrolled 119 adults with anti-AChR antibody-negative gMG. The study spanned sites across North America, Europe, China, and the Middle East.
This wasn't a small open-label study where everyone gets the drug and you hope the numbers look good. This was the gold standard of clinical trial design: patients randomly assigned to Vyvgart or placebo, with neither the patients nor the doctors knowing who got what.
The primary endpoint measured changes in MG-ADL scores (a standardized way of tracking how much the disease interferes with daily activities like eating, talking, and breathing). Patients on Vyvgart showed rapid, significant, and sustained symptom improvements compared to placebo.
Think of it like this: if gMG is a volume dial that controls how weak your muscles are, Vyvgart turned that dial down quickly and kept it there.
How Vyvgart Actually Works (in Plain English)
Most autoimmune diseases share a common villain: antibodies that attack your own body instead of foreign invaders. In gMG, these rogue antibodies (a type called IgG) target the neuromuscular junction, the spot where nerves tell muscles to move.
Your body has a built-in recycling system for IgG antibodies. A protein called the neonatal Fc receptor (FcRn) acts like a bodyguard, rescuing IgG antibodies from being destroyed and sending them back into circulation. Under normal circumstances, this is a helpful feature. When those antibodies are attacking your own muscles? Not so much.
Vyvgart is a first-in-class IgG1 antibody fragment that blocks FcRn, essentially firing the bodyguard. Without FcRn protection, disease-causing antibodies get broken down faster. Fewer rogue antibodies means less damage to the neuromuscular junction, which means less muscle weakness.
The elegant part: because FcRn recycles all IgG antibodies regardless of which specific autoantibody is causing trouble, Vyvgart doesn't care whether you're AChR-positive, MuSK-positive, LRP4-positive, or triple seronegative. It goes after the shared upstream problem. That's precisely why it works across all serotypes.
From Niche Drug to $4 Billion Juggernaut
Vyvgart's commercial trajectory has been nothing short of extraordinary. When it launched in late 2021, it was a promising drug for a subset of a rare disease. Fast-forward to 2025, and argenx posted $4.2 billion in product net sales, representing roughly 90% growth over 2024's already impressive $2.2 billion.
To put that growth rate in perspective: argenx nearly doubled its revenue while already at blockbuster scale. Most drugs see their growth rate decelerate as the numbers get bigger. Vyvgart has been doing the opposite.
The patient base tells a similar story. About 11,000 patients were on Vyvgart at the end of 2024. By the end of 2025, that number had climbed to approximately 19,000 patients globally. And that was before the seronegative label expansion opened the door to the remaining 20% of gMG patients.
The company crossed into operating profitability in 2025, posting $1.1 billion in operating profit. That's not tax-benefit accounting magic, either; it was driven by genuine commercial execution.
The FcRn Wars Are Heating Up
Vyvgart isn't fighting alone in the FcRn inhibitor space, though it has a considerable head start. UCB's Rystiggo (rozanolixizumab) won FDA approval for gMG in June 2023 with a subcutaneous-only formulation. Janssen's nipocalimab (branded as IMAAVY) has since received FDA approval for gMG and is commercially available in the US.
But argenx's lead looks increasingly durable. Rystiggo faces headwinds from high annual costs (ranging from $218,000 to $655,000 per year) and access challenges that have slowed its uptake.
Analysts at ODDO BHF project Vyvgart's peak sales could reach $14 billion by 2035, fueled by label expansions into additional autoimmune conditions like CIDP (chronic inflammatory demyelinating polyneuropathy, a nerve disease already approved) and primary immune thrombocytopenia.
The seronegative gMG expansion adds incremental revenue, but its strategic value is even larger: it cements Vyvgart as the default treatment across all of myasthenia gravis, making it harder for competitors to carve out niches.
What This Means for Patients (and for argenx's Pipeline)
For the roughly 20% of gMG patients who are seronegative, this approval is genuinely life-changing. These are people who've watched other patients get access to a targeted therapy while they waited on the sidelines. Now they have two options: the IV formulation (Vyvgart) and the subcutaneous version (Vyvgart Hytrulo), giving doctors flexibility in how they administer treatment.
For argenx, the approval validates a broader thesis: that FcRn inhibition is a platform, not a one-trick pony. The same mechanism that works across gMG serotypes could, in theory, work across any IgG-mediated autoimmune disease. The company's Phase 3 ADAPT OCULUS study recently hit its primary endpoint for ocular myasthenia gravis (a milder form limited to the eye muscles), adding another potential label expansion to the queue.
The pipeline extends well beyond MG. With $1.36 billion invested in R&D in 2025 alone, argenx is betting that Vyvgart's mechanism can travel.
The Bottom Line
Five years ago, Vyvgart was a promising drug for a narrow indication. Today it's a $4.2 billion franchise that just became the first therapy approved for every type of gMG. The Priority Review designation that started this process in January was the FDA's signal that seronegative patients had waited long enough. The May approval delivered on that promise.
In a biotech landscape littered with drugs that plateau after launch, Vyvgart keeps finding new patients and new indications to chase. For competitors trying to catch up, the target just got further away.
Funding & Financings
4 min read
The Pill That Could Rescue Myeloma Patients After Everything Else Fails
CellCentric just closed Europe's largest private biotech raise of 2026 to fund a first-in-class oral pill for myeloma patients who've failed everything else. The Phase 2 data show response rates double or triple the competition, and the investor list includes a very interesting pharma name.
